A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies.

"Declaration of Conflicting Interest: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HN received research funding from Astellas Pharma Inc, Novartis Pharma K.K., and honoraria from Astellas Pharma Inc, Kyowa Kirin Co, Ltd, NIPPON SHINYAKU Co, Ltd, and Novartis Pharma K.K. HO received honoraria from NIPPON SHINYAKU Co, Ltd. HK received research funding from Chugai Pharmaceutical Co, Ltd, and honoraria from Novartis Pharma K.K. YN received research funding from Astellas Pharma Inc, Novartis Pharma K.K., and honoraria from Chugai Pharmaceutical Co, Ltd, Kyowa Kirin Co, and Novartis Pharma K.K. MN (Nakamae) received honoraria from Novartis Pharma K.K. MN (Nishimoto) received research funding from Astellas Pharma Inc, and honoraria from Kyowa Kirin Co, TT received honoraria from Kyowa Kirin Co, Ltd and Sanofi K.K., and Novartis Pharma K.K. MH received research funding from Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd, Kyowa Kirin Co, Ltd, Novartis Pharma K.K., and honoraria from Astellas Pharma Inc and Chugai Pharmaceutical Co, Ltd, Kyowa Kirin Co, Ltd, NIPPON SHINYAKU Co, Ltd and Sanofi K.K. The other authors declare no conflicts of interest in association with the present study. This study was not supported by the pharmaceutical companies, and no patents or copyright issues exist."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Japan Society for the Promotion of Science (JSPS; KAKENHI Grant number 17K09017)."